```
=> b reg
FILE 'REGISTRY' ENTERED AT 07:50:52 ON 08 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 MAR 2007  HIGHEST RN 925228-12-2
DICTIONARY FILE UPDATES:    6 MAR 2007  HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l7
L4   (     35972)SEA FILE=REGISTRY ABB=ON  PLU=ON  >=2 NC5-C6/ES
L5               STR

Hy---N---Hy---N---Hy
 1   2   3   4   5


NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS UNLIMITED  AT   2  4

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   5

STEREO ATTRIBUTES: NONE
L6   (       330)SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L7            47 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND NCNC3/ES


=> b hcap
FILE 'HCAPLUS' ENTERED AT 07:51:03 ON 08 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 8 Mar 2007  VOL 146 ISS 11
FILE LAST UPDATED: 7 Mar 2007  (20070307/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l17 tot

L17 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:754380 HCAPLUS
DN 137:263071
TI Preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents
IN **Mailliet, Patrick**; **Laoui, Abdelazize**; **Riou, Jean-Francois**; Doerflinger, Gilles; **Mergny, Jean-Louis**; Hamy, Francois; Caulfield, Thomas
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2002076975	A1	20021003	2002WO-FR01005	20020322
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	FR---2822468	A1	20020927	2001FR-0003916	20010323
	CA---2442012	A1	20021003	2002CA-2442012	20020322
	EP---1373252	A1	20040102	2002EP-0720068	20020322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP2004524349	T	20040812	2002JP-0576233	20020322
	US2003087931	A1	20030508	2002US-0103883	20020325
	US---6887873	B2	20050503		
	US2005070571	A1	20050331	2004US-0993637	20041119
PRAI	2001FR-0003916	A	20010323		
	2001FR-0010370	A	20010802		
	2001US-332009P	P	20011123		
	2002WO-FR01005	W	20020322		
	2002US-0103883	A3	20020325		

OS MARPAT 137:263071
GI



I



II

AB Title compds. I [A = XR1R2; X = N, O, S, alkyl radical; R1-2 = H, alkyl, heterocyclyl, etc.; R3-3' = H, alkyl, isoquinolinyl, quinolinyl, etc.; Ar1-2 = (un)substituted Ph, etc., and derivs. thereof] were prepared For instance, 2,4-bis[(4-(dimethylamino)-2-methylquinolin-6-yl)amino]-6-chloro[1,3,5]triazine (prior art) was reacted with N,N-dimethyl-1,3-propanediamine in DMF with K2CO3 for 15 h at 100° to afford II. Examples include evaluation of all compds. of the invention for telomerase activity. I are anti-cancer agents.

IT **462649-59-8P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4-[pyrimidin-4-yl]piperazinyl]triazine **462649-65-6P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4-[pyrimidin-2-yl]piperazinyl]triazine **462649-99-6P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyrimidin-2-yl]amino]triazine **462650-15-3P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4,6-dimethylpyrimidin-2-yl]oxy]triazine **462650-17-5P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyrimidin-2-yl]oxy]triazine **462650-39-1P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[pyrimidin-2-yl]sulfanyl]triazine **462650-41-5P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[[4,6-dimethylpyrimidin-2-yl]sulfanyl]triazine **462650-96-0P**, 2-[[4-Dimethylamino-2-methylquinolin-6-yl]amino]-4-[[4-dimethylamino-2-methylquinolin-6-yl]amino]-6-[[pyrimidin-2-yl]amino]triazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)

IT **462649-59-8P**, 2-[[4-Amino-2-methylquinolin-6-yl]amino]-4-[[4-amino-2-methylquinolin-6-yl]amino]-6-[4-[pyrimidin-4-yl]piperazinyl]triazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of trisubstituted 2,4,6-triamino[1,3,5]triazines as anti-telomerase agents)

RN 462649-59-8 HCAPLUS
CN 4,6-Quinolinediamine, N6,N6'-[6-[4-(4-pyrimidinyl)-1-piperazinyl]-1,3,5-triazine-2,4-diyl]bis[2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:416931 HCAPLUS
DN 135:33495
TI Arylamine derivatives and their use as anti-telomerase agent
IN **Mailliet, Patrick; Riou, Jean-Francois; Mergny, Jean-Louis; Laoui, Abdelazize; Lavelle, Francois; Petitgenet, Odile**
PA Aventis Pharma S.A., Fr.
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2001040218	A1	20010607	2000WO-FR03310	20001127 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR---2801588	A1	20010601	1999FR-0015031	19991129 <--
FR---2801588	B1	20020301		
CA---2392507	A1	20010607	2000CA-2392507	20001127 <--
BR2000015992	A	20020806	2000BR-0015992	20001127 <--
EP---1244650	A1	20021002	2000EP-0985339	20001127 <--
EP---1244650	B1	20030625		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU-200204429	A2	20030428	2002HU-0004429	20001127 <--
JP2003515604	T	20030507	2001JP-0541902	20001127 <--
EE-200200263	A	20030616	2002EE-0000263	20001127 <--
AT----243692	T	20030715	2000AT-0985339	20001127 <--
PT---1244650	T	20031128	2000PT-0985339	20001127 <--
ES---2202206	T3	20040401	2000ES-0985339	20001127 <--
US---6645964	B1	20031111	2000US-0722361	20001128 <--

	NO2002002528	A	20020528	2002NO-0002528	20020528 <--
	ZA2002004266	A	20030828	2002ZA-0004266	20020528 <--
	BG----106753	A	20030228	2002BG-0106753	20020529 <--
	US2004053966	A1	20040318	2003US-0658394	20030910 <--
PRAI	1999FR-0015031	A	19991129	<--	
	2000FR-0010561	A	20000811	<--	
	2000US-176632P	P	20000119	<--	
	2000US-218059P	P	20000713	<--	
	2000WO-FR03310	W	20001127		
	2000US-0722361	A3	20001128	<--	

OS MARPAT 135:33495

AB Nitrogen heterocycles, especially diaminotriazines, were prepared for use as telomerase inhibitors and anticancer agents. Thus, 2-amino-4,6-dichloro-1,3,5-triazine was treated with 1-methyl-4,6-quinaldinium chloride hydrochloride to give 2-amino-4,6-bis(1-methyl-4-amino-6-quinaldinio)amino-1,3,5-triazine dichloride hydrochloride which was converted to its free base. The free base had a telomerase-inhibiting IC50 of 0.25 μM and a cytotoxic IC50 of 0.59-1.9 μM.

IT **343876-24-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

IT **343876-24-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

RN 343876-24-4 HCAPLUS

CN 4,6-Quinolinediamine, N6,N6'-2,4-pyrimidinediylbis[2-methyl-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'REGISTRY' ENTERED AT 07:08:07 ON 08 MAR 2007)
DEL HIS Y
ACT J394C22/A

L1 (35972) SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES
L2 STR
L3 330 SEA FILE=REGISTRY SUB=L1 SSS FUL L2

ACT J394C22A/A

L4 (35972) SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES
L5 STR

```
L6   (       330)SEA FILE=REGISTRY SUB=L4 SSS FUL L5
L7            47 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND NCNC3/ES
                 ---------

     FILE 'HCAPLUS' ENTERED AT 07:10:07 ON 08 MAR 2007
L8             6 L7
L9             1 (US2004053966 OR US6645964)/PN OR (US2003-658394 OR US2000-7223
                 E MAILLIET P/AU
L10           73 E3-4
                 E RIOU J/AU
L11          235 E3-4,E9-12
                 E MERGNY J/AU
L12           86 E4-5
                 E LAOUI A/AU
L13           30 E3-5
                 E LAVELLE F/AU
L14           88 E3,E8
                 E PETITGENET O/AU
L15            5 E3-4
L16            1 (FR2000-10561 OR FR99-15031)/AP,PRN
L17            2 L8 AND L9-16
L18            4 L8 NOT L17

     FILE 'MEDLINE' ENTERED AT 07:42:12 ON 08 MAR 2007
L19            0 L7

     FILE 'EMBASE' ENTERED AT 07:42:23 ON 08 MAR 2007
L20            0 L7

     FILE 'BIOSIS' ENTERED AT 07:42:30 ON 08 MAR 2007
L21            0 L7

     FILE 'USPATFULL, USPAT2' ENTERED AT 07:42:36 ON 08 MAR 2007
L22           10 L7
L23            2 L22 AND L9,L16
L24            8 L22 NOT L23
L25            0 L24 AND (PY<=2000 OR AY<=2000 OR PRY<=2000)

     FILE 'TOXCENTER' ENTERED AT 07:45:39 ON 08 MAR 2007
L26            5 L7

=>
```